UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Name 2025 P 1147-13
Program Prior Authorization/Notification
Medications Esbriet® (pirfenidone)*and Ofev® (nintedanib)
P&T Approval Date 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 10/2019, 4/2020,
4/2021, 4/2022, 3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Esbriet (pirfenidone)* is a pyridone and Ofev (nintedanib) is a kinase inhibitor that are indicated
for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is also indicated for slowing the
rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial
lung disease (SSc-ILD) and for the treatment of chronic fibrosing interstitial lung diseases
(ILDs) with a progressive phenotype.
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Idiopathic pulmonary fibrosis
1. Initial Authorization
a. Esbriet* and Ofev will be approved based on the following criterion:
(1) Diagnosis of idiopathic pulmonary fibrosis
Authorization will be issued for 12 months
2. Reauthorization
a. Esbriet* will be approved based on the following criterion:
(1) Documentation of positive clinical response to Esbriet therapy
b. Ofev will be approved based on the following criterion:
(1) Documentation of positive clinical response to Ofev therapy
Authorization will be issued for 12 months
B. Systemic sclerosis-associated interstitial lung disease (Ofev only)
1. Initial Authorization
a. Ofev will be approved based on the following criterion:
© 2025 UnitedHealthcare Services, Inc.
1
(1) Diagnosis of systemic sclerosis-associated interstitial lung disease
Authorization will be issued for 12 months
2. Reauthorization
a. Ofev will be approved based on the following criterion:
(1) Documentation of positive clinical response to Ofev therapy
Authorization will be issued for 12 months
C. Chronic fibrosing interstitial lung disease with a progressive phenotype (Ofev only)
1. Initial Authorization
a. Ofev will be approved based on the following criterion:
(1) Diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive
phenotype
Authorization will be issued for 12 months
2. Reauthorization
a. Ofev will be approved based on the following criterion:
(1) Documentation of positive clinical response to Ofev therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Brand Esbriet is typically excluded from coverage. Tried/Failed criteria may be in place. Please
refer to plan specifics to determine exclusion status.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Esbriet [Prescribing Information]. Genentech USA, Inc. South San Francisco, CA. February
2023.
© 2025 UnitedHealthcare Services, Inc.
2
2. Ofev [Prescribing Information]. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.
October 2024.
Program Prior Authorization/Notification - Esbriet® (pirfenidone) and Ofev®
(nintedanib)
Change Control
11/2014 New Program
11/2015 Annual Review. No change to clinical content. Updated background.
9/2016 Annual Review. No change in coverage criteria. Updated references.
9/2017 Annual Review. No change in coverage criteria. Updated references.
9/2018 Annual Review. No change in coverage criteria. Updated references.
9/2019 Annual Review. No change in coverage criteria. Updated references.
10/2019 Added coverage criteria for systemic sclerosis for Ofev. Updated references.
4/2020 Updated background and added Ofev coverage criteria for chronic fibrosing
interstitial lung diseases with a progressive phenotype. Updated reference.
4/2021 Annual Review. No change in coverage criteria. Updated references.
4/2022 Annual Review. No change in coverage criteria. Updated references.
3/2023 Annual Review. Reformatted reauthorization criteria for Esbriet and Ofev for
Idiopathic Pulmonary Fibrosis. Added exclusion footnote for Brand Esbriet.
Added state mandate footnote and updated references.
3/2024 Annual review. No change in coverage criteria. Updated references.
3/2025 Annual review. No change in coverage criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3